SCHEMBL3534652

SCHEMBL3534652

Cn1c(-c2n[nH]c3ccc(Oc4cccc(F)c4)cc23)nc2cc(C(F)(F)F)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.39
CYP3A4 P08684 2/20 0.39
RAF1 P04049 3/20 0.38
MAP2K4 P45985 3/20 0.38
MAPK1 P28482 2/20 0.38
MAPKAPK3 Q16644 2/20 0.38
MAPK6 Q16659 2/20 0.38
MAPKAPK2 P49137 1/20 0.38
PDPK1 O15530 1/20 0.37
KDR P35968 3/20 0.36
KIT P10721 2/20 0.36
FLT3 P36888 2/20 0.36
TEK Q02763 2/20 0.36
STK25 O00506 1/20 0.36
CIT O14578 1/20 0.36
EPHB6 O15197 1/20 0.36
MAP3K7 O43318 1/20 0.36
RIPK2 O43353 1/20 0.36
PAK3 O75914 1/20 0.36
STK10 O94804 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3536898 0.92 BRAF (0.41) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3538588 0.92 MAP2K4 (0.39) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3539940 0.91 CACNA1D (0.42) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3535697 0.88 HTR2B (0.41) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3532970 0.88 CACNA1D (0.42) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3536897 0.87 KDM4E (0.43) MAPK1PDPK1KITFLT3ABL1
SCHEMBL3542562 0.86 BRAF (0.39) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3535847 0.86 TRPV1 (0.42) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3540348 0.86 BRAF (0.38) BRAFCYP3A4RAF1MAP2K4MAPK1
SCHEMBL3541984 0.85 ABL1 (0.42) BRAFCYP3A4RAF1MAP2K4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK BRAF 74/4885CYP3A4 584/4885RAF1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.